XTL Biopharmaceuticals 98389BAV2 Bond
XTLB Stock | USD 1.88 0.03 1.62% |
At present, XTL Biopharmaceutica's Short Term Debt is projected to decrease significantly based on the last few years of reporting. The current year's Interest Debt Per Share is expected to grow to 0.000057, whereas Net Debt is forecasted to decline to (1.5 M). With a high degree of financial leverage come high-interest payments, which usually reduce XTL Biopharmaceutica's Earnings Per Share (EPS).
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
XTL |
Given the importance of XTL Biopharmaceutica's capital structure, the first step in the capital decision process is for the management of XTL Biopharmaceutica to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of XTL Biopharmaceuticals Ltd to issue bonds at a reasonable cost.
Popular Name | XTL Biopharmaceutica XCEL ENERGY INC |
Specialization | Pharmaceuticals, Biotechnology & Life Sciences |
Equity ISIN Code | US98386D3070 |
Bond Issue ISIN Code | US98389BAV27 |
S&P Rating | Others |
Maturity Date | Others |
Issuance Date | Others |
Coupon | 4.0 % |
XTL Biopharmaceuticals Outstanding Bond Obligations
XEL 46 01 JUN 32 | US98388MAD92 | Details | |
Dana 575 percent | US235822AB96 | Details | |
XEL 235 15 NOV 31 | US98388MAC10 | Details | |
XEL 175 15 MAR 27 | US98388MAB37 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
XCEL ENERGY INC | US98389BAU44 | Details | |
XCEL ENERGY INC | US98389BAV27 | Details | |
XCEL ENERGY INC | US98389BAR15 | Details | |
HSBC Holdings PLC | US404280DR76 | Details | |
XCEL ENERGY INC | US98389BAN01 | Details | |
XCEL ENERGY INC | US98389BAH33 | Details | |
US98389BBB53 | US98389BBB53 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
XTO ENERGY INC | US98385XAM83 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details |
Understaning XTL Biopharmaceutica Use of Financial Leverage
XTL Biopharmaceutica's financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures XTL Biopharmaceutica's total debt position, including all outstanding debt obligations, and compares it with XTL Biopharmaceutica's equity. Financial leverage can amplify the potential profits to XTL Biopharmaceutica's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if XTL Biopharmaceutica is unable to cover its debt costs.
Last Reported | Projected for Next Year | ||
Net Debt | -1.4 M | -1.5 M | |
Short Term Debt | 578.7 K | 1 M | |
Short and Long Term Debt Total | 952.2 K | 904.6 K | |
Net Debt To EBITDA | 1.83 | 1.11 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:Check out the analysis of XTL Biopharmaceutica Fundamentals Over Time. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (0.03) | Return On Assets (0.14) | Return On Equity (0.13) |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.